For research use only.
CAS No. 908115-27-5
PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.
Selleck's PF-04929113 (SNX-5422) has been cited by 4 publications
3 Customer Reviews
Effect of SNX-2112 on E. histolytica morphology. Trophozoites were treated with 3 uM SNX-2112 for 48 h. (A) E. histolytica trophozoites treated with 0.5% DMSO. Arrow indicates live trophozoite. Magnification, x 10. (B) E. histolytica trophozoites treated with 3 uM SNX-2112. Treatment caused complete lysis of trophozoites (arrow). Magnification, x 10. Trophozoites were imaged under phase-contrast microscope.
Antimicrob Agents Chemother 2014 58(7), 4138-44. PF-04929113 (SNX-5422) purchased from Selleck.
8505C and CAL62 cells were treated with SNX5422 at 5 μM for 72 h, and the protein levels of hsp90, hsp70, Raf-1, GSK3b, and total and phospho-Akt were measured. All experiments were performed in triplicate. The blots are representative of independent experiments.
Endocrine, 2016, 51(2):274-82.. PF-04929113 (SNX-5422) purchased from Selleck.
Purity & Quality Control
Choose Selective HSP (HSP90) Inhibitors
|Description||PF-04929113 (SNX-5422) is a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2.|
PF-04929113 is a small-molecule Hsp90 inhibitor based on the 6,7-dihydro-indazol-4-one scaffold. PF-04929113 developed by Serenex, converts to SNX-2122, which is the active Hsp90 inhibitor form. PF-04929113 exhibits potent effects on Her-2 stability and causes expected up-regulation of Hsp70. PF-04929113 shows potent antiproliferative activity against a broad range of cancer cell types, e.g. MCF-7 (IC50=16 nM), SW620 (IC50=19 nM), K562 (IC50=23 nM), SK-MEL-5 (IC50=25 nM), and A375 (IC50=51 nM).